NCT03075696: An ongoing trial by Hoffmann-La Roche
This trial is ongoing. It must report results 5 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03075696 |
|---|---|
| Title | A Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 21, 2017 |
| Completion date | Dec. 31, 2029 |
| Required reporting date | Dec. 31, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |